Form 4: Lilly Endowment Disposes 113,694 Eli Lilly Shares on 09/30/2025
Rhea-AI Filing Summary
Lilly Endowment Inc., a reporting person and director-related holder of Eli Lilly & Co. (LLY) stock, reported multiple open-market sales on 09/30/2025. The Form 4 shows four sell transactions totaling 113,694 shares sold at weighted-average prices of approximately $763.095, $764.355, $765.44, and $766.117, executed across price ranges disclosed in footnotes. After these disposals the reporting person beneficially owned 95,492,993 shares. The filing is signed by Diane M. Stenson, Vice President & Treasurer, on behalf of Lilly Endowment Inc., and offers to provide transaction-level price details on request.
Positive
- None.
Negative
- None.
Insights
TL;DR: Reporting entity sold 113,694 LLY shares on 09/30/2025, leaving ~95.5 million shares beneficially owned; transactions appear routine.
The aggregate sale of 113,694 shares represents roughly 0.12% of the reported post-transaction holdings of 95,492,993 shares, indicating these disposals are small relative to total ownership. Prices are reported as weighted averages with ranges provided, and the filer offers to supply transaction-level details on request. No derivative transactions or other unusual transfers are reported. From a liquidity and signaling perspective, the filing documents compliance with Section 16 disclosure obligations without evidence of material change to ownership concentration.
TL;DR: Form 4 discloses routine open-market sales by a significant institutional holder; disclosure appears complete and timely.
The Form 4 is signed by an authorized officer and includes weighted-average pricing with explanatory footnotes, meeting disclosure norms. The report certifies willingness to provide detailed trade-level information, which supports transparency. There are no indications of an amendment or corrective disclosure, and no derivative holdings reported. The filing is relevant for monitoring insider activity but does not, on its face, raise governance or compliance concerns.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 90,501 | $763.095 | $69.06M |
| Sale | Common Stock | 19,492 | $764.355 | $14.90M |
| Sale | Common Stock | 2,649 | $765.44 | $2.03M |
| Sale | Common Stock | 1,052 | $766.117 | $806K |
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $763.00 to $763.9997, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1), (2), (3), and (4) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $764.00 to $764.9996, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $765.0001 to $765.9974, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $766.0029 to $766.2333, inclusive.
